Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

How To interpret results from Next Generation Sequencing reports?

In this educational video of the 'How To' series, Christophe Le Tourneau explains when to test, how to interpret the results from Next Generation Sequencing reports and manage patients expectations.

In the metastatic setting NGS can be helpful to identify molecular alterations and then direct patients to the relevant clinical trial. Because of the NGS report complexity, results should always be discussed in a molecular tumour board including a medical oncologist, a pathologist and a biologist.

Reprinted from Lancet Oncology, 16 /13, Le Tourneau C. et al., Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial, Copyright (2015), with permission from Elsevier

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings